NCT lookup

Pull any trial record directly from ClinicalTrials.gov.

Identifying Atopic Dermatitis Patients at Risk for Developing Conjunctivitis During Dupilumab Treatment

UnknownN/A

Sponsor: UMC Utrecht

Conditions: Atopic Dermatitis

Countries: Netherlands

Study on ophthalmological comorbidities and the underlying pathomechanisms of conjunctivitis during dupilumab treatment in atopic dermatitis (AD) patients. Patients participate in the Bioday Registry.

Eligibility overview

Sex: ALL

Age: 18 Years to —

Healthy volunteers: No

Study type: OBSERVATIONAL

Eligibility criteria

Inclusion Criteria:

* Adult patients with atopic dermatitis indicated for dupilumab, without current use of oral immunosuppressive treatment .

Exclusion Criteria:

* Treatment with oral or ocular immunosuppressive drugs 2 weeks prior to start of dupilumab treatment

Locations (1)

Utrecht, Netherlands